1 February 2022
NZ pigs possible key to treating Parkinson's
Investor Centre
Living Cell Technologies Ltd (LCT)
LCT:ASX • Healthcare
0.011
UN
CH.
CH.
0.00
(0.00)
VOLUME
734460
52 WEEK RANGE
0.005 - 0.018
1 YR RETURN
-0
Key Information
MARKET CAPITALISATION
$15601400
Novel therapies for serious diseases
LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions such as Parkinson’s disease, obesity and migraine.
Our product candidates leverage the potential of cells and their receptors to address serious conditions that have an unmet need for effective treatments.
We are listed on both the Australian Securities Exchange (ASX:LCT) and the international OTCQB (LVCLY). Share registry services are provided by Automic.
